

# Hepcludex<sup>®</sup> (bulevirtide-gmod) Use in HCV Co-Infection

This document is in response to your request for information regarding the use of Hepcludex<sup>®</sup> (bulevirtide-gmod [BLV]) for the treatment of chronic HDV infection in patients with HCV.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

**The full indication, important safety information, and boxed warnings are available at: [www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex_pi).**

---

## Product Labeling<sup>1</sup>

There is no information in the BLV US Prescribing Information regarding the use of BLV in patients with HCV.

BLV is indicated for the treatment of chronic HDV infection in adults without cirrhosis or with compensated cirrhosis.

This indication is approved under accelerated approval based on a decrease in HDV RNA and ALT normalization. An improvement in disease-related clinical outcomes has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

The recommended dosage in adults is BLV 8.5 mg once daily administered by subcutaneous injection.

No dosage adjustment of BLV is recommended in patients with mild hepatic impairment (Child-Pugh Class A). The safety and efficacy of BLV have not been studied in patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment.

In a phase 1, open-label study in participants without HDV infection, the steady-state pharmacokinetics of BLV were approximately 27% lower in participants with moderate hepatic impairment (Child-Pugh Class B) than participants with normal hepatic function. The steady state pharmacokinetics of BLV were similar among participants with severe hepatic impairment (Child-Pugh Class C) and participants with normal hepatic function.

The efficacy of BLV once daily in the treatment of adults with chronic HDV infection without cirrhosis or with compensated cirrhosis is based on data through Week 144 from a multicenter, randomized, open-label, parallel-arm phase 3 trial, Trial MYR301 (NCT03852719), in which 100 participants received BLV 8.5 mg once daily. The MYR301 protocol specified the BLV dose as 10 mg; however, a dose recovery study later showed that the delivered dose was 8.5 mg.

## Clinical Data on BLV Use in HCV Co-Infection

In a phase 3 study (MYR301) and phase 2/2b clinical studies (MYR202, MYR203, and MYR204), participants co-infected with HCV infection were excluded. Participants with anti-HCV antibodies could be enrolled if the screening HCV RNA test was negative.<sup>2-5</sup>

## Literature Search

Additionally, a literature search was conducted in Ovid MEDLINE and Embase databases for studies published up to March 11, 2026, using the search terms of Hepcludex, bulevirtide, hepatitis C, HCV, HDV, and related search terms. No relevant citations were found.

---

## References

1. Enclosed. Gilead Sciences Inc. HEPCLUDEX® (bulevirtide-gmod) injection, for subcutaneous use. US Prescribing Information. Foster City, CA.
2. Wedemeyer H, Schoneweis K, Bogomolov P, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. *Lancet Infect Dis.* 2022.
3. Wedemeyer H, Aleman S, Brunetto MR, et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. *N Engl J Med.* 2023;389(1):22-32.
4. Lampertico P, Bogomolov PO, Chulanov V, et al. Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNalpha-2a as Treatment for Chronic Hepatitis Delta [Supplement]. *Liver Int.* 2025;45(2):e70008.
5. Asselah T, Chulanov V, Lampertico P, et al. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D [Protocol]. *N Engl J Med.* 2024;391(2):133-143.

---

## Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Hepcludex US Prescribing Information available at:

[www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex_pi).

## Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 [www.askgileadmedical.com](http://www.askgileadmedical.com)

## Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or

🌐 [www.gilead.com/utility/contact/report-an-adverse-event](http://www.gilead.com/utility/contact/report-an-adverse-event)

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 [www.accessdata.fda.gov/scripts/medwatch](http://www.accessdata.fda.gov/scripts/medwatch)

## Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement ([www.gilead.com/privacy-statements](http://www.gilead.com/privacy-statements)) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact [gilead.privacy@gilead.com](mailto:gilead.privacy@gilead.com).

HEPCLUDEX, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.